75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed in all patients with 81% of EVX-01’s vaccine targets triggering a specific responseTreatment was well toleratedData is presented today at the ESMO Congress and will be discussed at a webinar with key opinion leader Professor Muhammad Adnan Khattak on October 22, 2025 COPENHAGEN, Denmark, October 17, 2025 - ...

Core Insights - BriaCell Therapeutics Corp. has received a non-dilutive research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and reduce the costs associated with traditional personalized cancer treatments, addressing an urgent unmet medical need in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its personalized off-the-shelf immunotherapy approach, which is expected to significantly improve personalized cancer treatment [4][7] Clinical Study Insights - Dr. William Oh, the Principal Investigator for the upcoming clinical study, emphasized the need for effective treatments for metastatic hormone-sensitive prostate cancer, highlighting the urgency of the medical need [3] - The Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients suffering from advanced prostate cancer [2][3]

Core Insights - BriaCell Therapeutics Corp. has received a research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and expedite personalized cancer treatments, addressing significant unmet medical needs in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its Bria-PROS+ platform, which is designed to provide off-the-shelf personalized immunotherapy solutions [4][7] Clinical Development - The upcoming Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients with metastatic prostate cancer, a condition with limited treatment options [3][7] - Dr. William Oh from Yale Cancer Center is the Principal Investigator for the clinical study, highlighting the urgency of addressing unmet medical needs in this area [3][7]